Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy

References

• Hocht S, Aebersold DM, Albrecht C, et al. Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2017;193:1–12.
   PubMed Web of Science ®Google Scholar
• Arcangeli S, Greco C. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? Nat Rev Urol. 2016;13:400–408.
   PubMed Web of Science ®Google Scholar
• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol. 2012;51:963–974.
   PubMed Web of Science ®Google Scholar
• Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884–1890.
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Saracino B, Arcangeli S, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial. J Clin Oncol. 2017;35:1891–1897.
   PubMed Web of Science ®Google Scholar
• Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. JCO. 2016;34:2325–2332.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047–1060.
   PubMed Web of Science ®Google Scholar
• Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17:1061–1069.
   PubMed Web of Science ®Google Scholar
• Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31:3860–3868.
   PubMed Web of Science ®Google Scholar
• Kuban DA, Nogueras-Gonzalez GM, Hamblin L, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys. 2010;78:S58–S59.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: what is it, really? Radiother Oncol. 2005;76:1–3.
   PubMed Web of Science ®Google Scholar
• Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005;44:265–276.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E, et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82:e17–e24.
   PubMedGoogle Scholar
• Fowler JF, Ritter MA, Chappell RJ, et al. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;56:1093–1104.
   PubMed Web of Science ®Google Scholar
• Shaffer R, Pickles T, Lee R, et al. Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure. Int J Radiat Oncol Biol Phys. 2011;79:1029–1036.
   PubMed Web of Science ®Google Scholar
• Oliveira SM, Teixeira NJ, Fernandes L. What do we know about the alpha/beta for prostate cancer? Med Phys. 2012;39:3189–3201.
   PubMed Web of Science ®Google Scholar
• Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol). 2007;19:289–301.
   PubMed Web of Science ®Google Scholar
• Ray KJ, Sibson NR, Kiltie AE. Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits. Clin Oncol (R Coll Radiol). 2015;27:420–426.
   PubMed Web of Science ®Google Scholar
• Lennernas B, Nilsson S, Levitt S. Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio–possible reasons for concerns? An example of five dimensional radiotherapy. Acta Oncol. 2011;50(Suppl. 1):111–115.
   PubMed Web of Science ®Google Scholar
• Høyer M. What does large randomized trials tell us about the fractionation sensitivity of prostate cancer? J Phys Conf Ser. 2017;777:012024. Available from: http://iopscience.iop.org/article/10.1088/1742-6596/777/1/012024
   Google Scholar
• Cosset JM. [Hypofractionated irradiation of prostate cancer: what is the radiobiological understanding in 2017?]. Cancer Radiother. 2017;21:447–453.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Ritter MA. A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 1995;32:521–529.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974.
   PubMed Web of Science ®Google Scholar
• Thames HD, Kuban D, Levy LB, et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol. 2010;96:6–12.
   PubMed Web of Science ®Google Scholar
• Comprehensive Meta-Analysis [Internet]. Comprehensive Meta-Analysis Software, version 3.0. 2016 [Aug 8.]. Englewood, NJ: Biostat. Available from: https://www.meta-analysis.com/
   Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.
   PubMed Web of Science ®Google Scholar
• Hoffman KE, Voong KR, Pugh TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014;88:1074–1084.
   PubMed Web of Science ®Google Scholar
• Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66:1072–1083.
   PubMed Web of Science ®Google Scholar
• Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. JCO. 2005;23:6132–6138.
   PubMed Web of Science ®Google Scholar
• Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys. 2011;81:1271–1278.
   PubMed Web of Science ®Google Scholar
• Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380–385.
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Palmer JD, Hurwitz MD, et al. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015;115:295–300.
   PubMed Web of Science ®Google Scholar
• Gulliford S, Griffin C, Tree A, et al. Estimates of the α/β ratio for prostate using data from recent hypofractionated RT trials. Radiother Oncol. 2017;123:S871–S872.
   Web of Science ®Google Scholar
• Zumsteg ZS, Zelefsky MJ. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol. 2012;13:e259–e269.
   PubMed Web of Science ®Google Scholar
• Castle KO, Hoffman KE, Levy LB, et al. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013;85:693–699.
   PubMed Web of Science ®Google Scholar
• Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.
   PubMedGoogle Scholar
• Munoz-Moreno L, Arenas MI, Carmena MJ, et al. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer. Oncotarget. 2016;7:52195–52206.
   PubMedGoogle Scholar
• Katzenwadel A, Wolf P. Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett. 2015;367:12–17.
   PubMed Web of Science ®Google Scholar
• Ardiani A, Gameiro SR, Kwilas AR, et al. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014;5:9335–9348.
   PubMed Web of Science ®Google Scholar
• Roberts SA, Hendry JH, Brewster AE, et al. The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor. Br J Radiol. 1994;67:790–794.
   PubMed Web of Science ®Google Scholar
• Hansen O, Overgaard J, Hansen HS, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol. 1997;43:47–51.
   PubMed Web of Science ®Google Scholar
• Datta NR, Stutz E, Rogers S, et al. Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: a systematic review and meta-analysis along with therapeutic implications. Int J Radiat Oncol Biol Phys. 2017;99:573–589.
   PubMed Web of Science ®Google Scholar
• De Bari B, Arcangeli S, Ciardo D, et al. Extreme hypofractionation for early prostate cancer: biology meets technology. Cancer Treat Rev. 2016;50:48–60.
   PubMed Web of Science ®Google Scholar
• Nahum AE. The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol). 2015;27:260–269.
   PubMed Web of Science ®Google Scholar
• Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:847–852.
   PubMed Web of Science ®Google Scholar
• Lennernas B, Castellanos E, Nilsson S, et al. Four and five dimensional radiotherapy with reference to prostate cancer–definitions, state of the art and further directions–an overview. Acta Oncol. 2011;50(Suppl. 1):104–110.
   PubMed Web of Science ®Google Scholar